XI’AN, China, July 23 /Xinhua-PRNewswire-FirstCall/ -- Skystar
Bio-Pharmaceutical Co., Ltd. (OTC Bulletin Board: SKBI) (“Skystar”; “Company”), a leading bio-pharmaceutical company in the People’s Republic of China (“PRC”), today announced that it has successfully developed a first aid kit to treat the recent outbreak of Swine High-Fever Syndrome (“SHFS”) among pigs in China. The kit is expected to generate about $526,000 in revenue during the second half of 2007.
SHFS is caused by mutated viral strains of porcine reproductive and respiratory syndrome, also know as blue ear disease, and is often complicated by porcine circovirus type 2 (PCV-2). The complication evolves in three stages. First, the viral infection damages pigs’ immune system resulting in immunity paralysis or complete loss of immunity. Consequently, primary mixed infections usually follow including many other viral diseases such as hog cholera, pseudorabies, cephalitis B, parvovirus, rotavirus and influenza. Further, complicated viral infections lead to secondary mixed infections caused by highly contagious bacterial diseases such as streptococcemia, pleuropneumonia, colibacillosis, pasteurellosis and mycoplasma pneumonia. As a direct result of blue ear disease, SHFS often results in rapid infection and extremely high mortality rates.
Skystar’s research and development team has spent more than six months developing the kit to effectively treat SHFS and increase recovery rates. The Company has developed prevention and treatment therapies specifically designed for large-scale pig farms. The first aid kit for SHFS was launched in China at the beginning of July under the marketing campaign “Operation Blue Sword.”
“We are excited to launch our SHFS first aid kit this July which coincides with Skystar’s 10th anniversary as a bio-pharmaceutical company. The kit specifically targets the associated complications caused by the recent rampant spread of blue ear disease in China. Operation Blue Sword demonstrates our strong R&D capability as well as our quick response to market trends,” commented Mr. Weibing Lu, Chairman and Chief Executive Officer of Skystar. “The kit has been clinically proven to cure blue ear disease induced complications and we expect it will significantly contribute to Skystar’s revenues and brand-name recognition.”
The kit combines two newly developed Western medicines and one newly developed Traditional Chinese Medicine which contains a wealth of agents to strengthen the immune system such as 3R factors, plant amylase, hypericin, echinacea, peculiar mycelium, immunity booster, polypeptide and interferon inducer. As a result, the kit significantly increases the amount of macrophages, T cells and B cells within the pig’s body and thus rapidly boosts the immunity system. By killing pathogenic microorganisms including bacteria and mycoplasma, the kit cures secondary infections caused by bacterial diseases and by enhancing the pig’s immune system, the kit effectively stimulates the antibody response and thus controls primary infections caused by viral diseases. Once the primary and secondary infections are controlled and cured, the pig’s immune system will normally generate enough antibodies to fight the blue ear disease and thus effectively restrain the virus. The Company’s clinical trials, which were held in almost 1,000 large-scale pig farms in Guangxi, Guangdong, Jiangsu, Hunan and Shanxi Province, demonstrated an effective rate as high as 98.7% and the cure rate for primary and secondary infections was above 80%.
About Skystar Bio-Pharmaceutical
Skystar Bio-Pharmaceutical Company is a China-based producer and distributor of vaccines, microorganisms and veterinary medication to cure and prevent disease in poultry, livestock, birds and pets. The Company’s product line consists of more than 100 products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. The Company recently completed the first phase of construction of new state-of-the-art bio-pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com/ .
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains certain “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events including revenues and gross margins could differ materially from management’s current expectations. Such factors include, but are not limited to the acceptance of the company’s SHFS first aid kit in the Chinese market the company’s ability to accurately complete product orders, coordinate product design with its customers, ability to expand and grow its distribution channels, market acceptance of new products, competitive pressures, scale-up of manufacturing, political and economic factors in the People’s Republic of China, the company’s ability to find attractive acquisition candidates, dependence on a limited number of larger customers and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
